Introduction to Immune deficiencies
Immune Deficiency disorders prevent the body from fighting infections. This makes it easier for patients to catch viruses and bacterial infections. Immunodeficiency disorders are either congenital or acquired. A congenital, or primary, disorder is one patients are born with. Acquired, or secondary, disorders appear later in life and are more common than congenital disorders.
People with primary immune deficiency lack immunoglobulins (antibodies) - unique proteins in the blood that fight infections and are important for a well-functioning immune system. Those suffering from primary immune deficiency often have a diminished quality of life due to the increased risk of infections and viruses. However, with proper medical care, many people live full and independent lives.
Immunoglobulin therapy is one of several effective medical therapies available to treat primary immune deficiency. To replace the missing immunoglobulins, extra immunoglobulins are prepared from the blood plasma from healthy donors and injected into the blood by infusion, administered subcutaneously or intravenously. This is replacement therapy and is necessary for the rest of a patient's life.
The neria product range
neria™ infusion sets are tested (in vitro) for use with immunoglobulin therapy.1
The neria product range offers a wide range of infusion sets with different features to help support the best possible treatment for patients.
For a complete overview of our neria™ infusion set range, including specifications, please see the table below. The table is also available as a pdf download.
| Product Specifications | neria™ | neria™ detach | neria™ multi | neria™ soft | neria™ soft 90 | neria™ guard |
|---|---|---|---|---|---|---|
| Cannula | Stainless Steel | Stainless Steel | Stainless Steel | Soft | Soft | Soft |
| Insertion angle | 90 degrees | 90 degrees | 90 degrees | 20-45 degrees | 90 degrees | 90 degrees |
| Disconnection feature | No | Yes | No | Yes at site | Yes at site | Yes at site |
| Needle / Introducer needle guage | G27 or G29 | G27 | G27 | G27 | G27 | G27 |
| Needle lengths | 6, 8 10 or 12 mm | 6,8 or 10mm | Bi-furcated: 8, 10mm Tri-furcated: 8, 10 or 12mm Quad-furcated: 8, 10, 12mm |
13 or 17mm | 6 or 9 mm | 6 or 9 mm |
| Tubing lengths | 60, 80, 110 cm | 60, 80, 110 cm | Total 90 cm | 30, 60, 80, 110 cm | 30, 60, 110 cm | 12, 30, 60, 80, 110 cm |
| Adhesive | Built-in | Built-in | Built-in | Built-in | Built-in | Built-in |
| Needle safety | - | - | - | - | Yes | Yes |
| Priming volumes | 60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
Bi-furcated ~ 0.36 ml Tri-furcated ~ 0.43 ml Quad-furcated ~ 0.51 ml |
30 cm @ 0.06 ml 60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
30 cm @ 0.06 ml 60 cm @ 0.10 ml 110 cm @ 0.15 ml |
12 cm @ 0.04 ml 60 cm @ 0.10 ml 80 cm @ 0.12 ml 110 cm @ 0.15 ml |
1. Statement - Overview of Drug/Device Compatibility Test for the neria™ Range. 24. February 2020. AP-020446-MM. Data on file. Unomedical A/S.
Flowrates and high viscosity medication
The number of sites and needle size can influence the flow of medication. Depending on the drug indication, the dosage can be distributed over several sites to decrease the total infusion time and ensure correct infusion volume per site. The viscosity (thickness) of the immunoglobulins can also vary depending on the drug brand and handling instructions. Using a larger needle gauge size (larger inner dimension of the needle) can help support appropriate flow. Soft catheter infusion sets often have larger inner dimensions (see example on the left*) and can be an alternative to a larger steel needle.
Always consult your healthcare professional to discuss the appropriate needle/catheter size and number of sites for your individual treatment.
*The soft catheter dimensions shown on this page are messuared in the middle of the catheter, not at the tip.
Resources
Find relevant clinical literature about immune deficiencies and continuous subcutaneous infusion management below:
Alessandra Vultaggio 1, Chiara Azzari, Cinzia Milito, Andrea Finocchi, Claudia Toppino, Giuseppe Spadaro, Antonino Trizzino, Martire Baldassarre, Roberto Paganelli, Viviana Moschese, Annarosa Soresina, Andrea Matucci
Clin Drug Investig. 2015 Mar;35(3):179-85
Ann Gardulf, Uwe Nicolay, Dipl Math, Oscar Asensio, Ewa Bernatowska, Andreas Böck, Beatriz T Costa-Carvalho, Carl Granert, Stefan Haag, Dolores Hernández, Peter Kiessling, Jan Kus, Nuria Matamoros, Tim Niehues, Sigune Schmidt, Ilka Schulze, Michael Borte
J Allergy Clin Immunol, 2004 Oct;114(4):936-42
Mary Elizabeth M Younger, Loris Aro, William Blouin, Carla Duff, Kristin B Epland, Elyse Murphy, Debra Sedlak, Nurse Advisory Committee Immune Deficiency Foundation
J Infus Nurs, Jan-Feb 2013;36(1):58-68
Hosein Shabaninejad, Asra Asgharzadeh, Nima Rezaei & Aziz Rezapoor
Expert Rev Clin Immunol, 2016;12(5):595-602
Ont Health Technol Assess Ser. 2017 Nov 1;17(16):1-86
Richard L Wasserman
Immunotherapy. 2017 Sep;9(12):1035-1050
Beate Bittner, Wolfgang Richter, Johannes Schmidt
BioDrugs 2018 Oct;32(5):425-440
